1
|
Ostadhossein F, Moitra P, Gunaseelan N, Nelappana M, Lowe C, Moghiseh M, Butler A, de Ruiter N, Mandalika H, Tripathi I, Misra SK, Pan D. Hitchhiking probiotic vectors to deliver ultra-small hafnia nanoparticles for 'Color' gastrointestinal tract photon counting X-ray imaging. NANOSCALE HORIZONS 2022; 7:533-542. [PMID: 35311837 DOI: 10.1039/d1nh00626f] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Gastrointestinal (GI) tract is one of the hard-to-reach target tissues for the delivery of contrast agents and drugs mediated by nanoparticles due to its harsh environment. Herein, we overcame this barrier by designing orally ingestible probiotic vectors for 'hitchhiking' ultrasmall hafnia (HfO2) (∼1-2 nm) nanoparticles. The minute-made synthesis of these nanoparticles is accomplished through a simple reduction reaction. These nanoparticles were incubated with probiotic bacteria with potential health benefits and were non-specifically taken up due to their small size. Subsequently, the bacteria were lyophilized and packed into a capsule to be administered orally as the radiopaque contrast agents for delineating the GI features. These nano-bio-hybrid entities could successfully be utilized as contrast agents in vivo in the conventional and multispectral computed tomography (CT). We demonstrated in 'color' the accumulated nanoparticles using advanced detectors of the photon counting CT. The enhanced nano-bio-interfacing capability achieved here can circumvent traditional nanoparticle solubility and delivery problems while offering a patient friendly approach for GI imaging to replace the currently practiced barium meal.
Collapse
Affiliation(s)
- Fatemeh Ostadhossein
- Department of Bioengineering, University of Illinois at Urbana-Champaign, 611 West Park Street, Urbana, IL, USA.
- Beckman Institute of Advanced Science and Technology, 405 N. Mathews M/C 251, Urbana, IL 61801-2325, USA
| | - Parikshit Moitra
- Departments of Diagnostic Radiology and Nuclear Medicine and Pediatrics, University of Maryland Baltimore, 670 W Baltimore St., Baltimore, Maryland, 21201, USA
| | - Nivetha Gunaseelan
- Departments of Diagnostic Radiology and Nuclear Medicine and Pediatrics, University of Maryland Baltimore, 670 W Baltimore St., Baltimore, Maryland, 21201, USA
- Department of Chemical, Biochemical and Environmental Engineering, University of Maryland Baltimore County, Baltimore, Maryland, 21250, USA
| | - Michael Nelappana
- Department of Bioengineering, University of Illinois at Urbana-Champaign, 611 West Park Street, Urbana, IL, USA.
| | - Chiara Lowe
- University of Otago Christchurch, Christchurch, New Zealand
| | - Mahdieh Moghiseh
- University of Otago Christchurch, Christchurch, New Zealand
- MARS Bioimaging Limited, Christchurch, New Zealand
| | - Anthony Butler
- University of Otago Christchurch, Christchurch, New Zealand
- MARS Bioimaging Limited, Christchurch, New Zealand
- University of Canterbury, Christchurch, New Zealand
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Human Interface Technology Laboratory New Zealand, University of Canterbury, Christchurch, New Zealand
| | - Niels de Ruiter
- University of Otago Christchurch, Christchurch, New Zealand
- MARS Bioimaging Limited, Christchurch, New Zealand
- University of Canterbury, Christchurch, New Zealand
- Human Interface Technology Laboratory New Zealand, University of Canterbury, Christchurch, New Zealand
| | - Harish Mandalika
- MARS Bioimaging Limited, Christchurch, New Zealand
- University of Canterbury, Christchurch, New Zealand
- Human Interface Technology Laboratory New Zealand, University of Canterbury, Christchurch, New Zealand
| | - Indu Tripathi
- Department of Bioengineering, University of Illinois at Urbana-Champaign, 611 West Park Street, Urbana, IL, USA.
| | - Santosh K Misra
- Department of Bioengineering, University of Illinois at Urbana-Champaign, 611 West Park Street, Urbana, IL, USA.
| | - Dipanjan Pan
- Department of Bioengineering, University of Illinois at Urbana-Champaign, 611 West Park Street, Urbana, IL, USA.
- Beckman Institute of Advanced Science and Technology, 405 N. Mathews M/C 251, Urbana, IL 61801-2325, USA
- Departments of Diagnostic Radiology and Nuclear Medicine and Pediatrics, University of Maryland Baltimore, 670 W Baltimore St., Baltimore, Maryland, 21201, USA
- Department of Chemical, Biochemical and Environmental Engineering, University of Maryland Baltimore County, Baltimore, Maryland, 21250, USA
- Department of Materials Science and Engineering, 201 Materials Science and Engineering Building, 1304 W. Green St. MC 246, Urbana, IL 61801, USA
| |
Collapse
|
2
|
Nozhat Z, Heydarzadeh S, Memariani Z, Ahmadi A. Chemoprotective and chemosensitizing effects of apigenin on cancer therapy. Cancer Cell Int 2021; 21:574. [PMID: 34715860 PMCID: PMC8555304 DOI: 10.1186/s12935-021-02282-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2021] [Accepted: 10/20/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Therapeutic resistance to radiation and chemotherapy is one of the major obstacles in cancer treatment. Although synthetic radiosensitizers are pragmatic solution to enhance tumor sensitivity, they pose concerns of toxicity and non-specificity. In the last decades, scientists scrutinized novel plant-derived radiosensitizers and chemosensitizers, such as flavones, owing to their substantial physiological effects like low toxicity and non-mutagenic properties on the human cells. The combination therapy with apigenin is potential candidate in cancer therapeutics. This review explicates the combinatorial strategies involving apigenin to overcome drug resistance and boost the anti-cancer properties. METHODS We selected full-text English papers on international databases like PubMed, Web of Science, Google Scholar, Scopus, and ScienceDirect from 1972 up to 2020. The keywords included in the search were: Apigenin, Chemoprotective, Chemosensitizing, Side Effects, and Molecular Mechanisms. RESULTS In this review, we focused on combination therapy, particularly with apigenin augmenting the anti-cancer effects of chemo drugs on tumor cells, reduce their side effects, subdue drug resistance, and protect healthy cells. The reviewed research data implies that these co-therapies exhibited a synergistic effect on various cancer cells, where apigenin sensitized the chemo drug through different pathways including a significant reduction in overexpressed genes, AKT phosphorylation, NFκB, inhibition of Nrf2, overexpression of caspases, up-regulation of p53 and MAPK, compared to the monotherapies. Meanwhile, contrary to the chemo drugs alone, combined treatments significantly induced apoptosis in the treated cells. CONCLUSION Briefly, our analysis proposed that the combination therapies with apigenin could suppress the unwanted toxicity of chemotherapeutic agents. It is believed that these expedient results may pave the path for the development of drugs with a high therapeutic index. Nevertheless, human clinical trials are a prerequisite to consider the potential use of apigenin in the prevention and treatment of various cancers. Conclusively, the clinical trials to comprehend the role of apigenin as a chemoprotective agent are still in infancy.
Collapse
Affiliation(s)
- Zahra Nozhat
- Institute of Smart Biomedical Materials, School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou, 310018 China
- Cellular and Molecular Endocrine Research Center, Research Institute of Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Shabnam Heydarzadeh
- Cellular and Molecular Endocrine Research Center, Research Institute of Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Department of Biochemistry, School of Biological Sciences, Falavarjan Branch Islamic Azad University, Isfahan, Iran
| | - Zahra Memariani
- Traditional Medicine and History of Medical Sciences Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
| | - Amirhossein Ahmadi
- Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| |
Collapse
|
3
|
Ji S, He DD, Su ZY, Du Y, Wang YJ, Gao SK, Guo MZ, Tang DQ. P450 enzymes-based metabolic interactions between monarch drugs and the other constituent herbs: A strategy to explore compatibility mechanism of Sangju-Yin. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2019; 58:152866. [PMID: 30831464 DOI: 10.1016/j.phymed.2019.152866] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 01/11/2019] [Accepted: 02/17/2019] [Indexed: 06/09/2023]
Abstract
BACKGROUND Herbal compatibility of compound formulas can enhance therapeutic effects or reduce side effects of the monarch drugs, but majority of compatibility mechanisms are still unknown. Sangju-Yin, a well-known Chinese compound formula, is currently used to treat common cold in clinical. PURPOSE In this study, we proposed a strategy to explore the compatibility mechanism of Sangju-Yin by investigating P450 enzymes-based metabolic interactions between monarch drugs and the other constituent herbs. METHODS Under the guidance of traditional Chinese medicine theory, the constituent herbs of Sangju-Yin were divided into four groups, including monarch drugs, monarch drugs with addition of minister drugs, monarch drugs with addition of minister and adjuvant drugs, as well as the whole recipe, namely monarch drugs with addition of minister, adjuvant and conductant drugs. Their effects on rats in vivo P450 (CYP1A2, CYP2A3, CYP2C6, CYP2C11 and CYP3A1) activities after oral administration were evaluated using probe drug assay based on LC-MS/MS. Moreover, effects of the four groups of herbs on mRNA expression of P450 enzymes after oral administration, as well as in vitro P450 activities after co-incubation, were investigated to explore the underlying mechanisms. RESULTS Comparing with monarch drugs, addition of different constituent herbs significantly enhanced CYP1A2 and CYP2C6 activities, and inhibited CYP2A3 and CYP3A1 activities, indicating their possible influences on plasma concentrations of active constituents in the monarch drugs. Mechanism study suggested that these herbs affected P450 activities by transcriptional regulation and/or direct interaction with the enzymes. CONCLUSION This study clarified the compatibility mechanism of Sangju-Yin from the aspect of P450 enzymes-based metabolic interactions, which would benefit better understanding of the therapeutic basis of Sangju-Yin.
Collapse
Affiliation(s)
- Shuai Ji
- Department of Pharmaceutical Analysis, Xuzhou Medical University, Xuzhou 221004, China; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, China
| | - Dan-Dan He
- Department of Pharmaceutical Analysis, Xuzhou Medical University, Xuzhou 221004, China
| | - Zhen-Yu Su
- Department of Pharmaceutical Analysis, Xuzhou Medical University, Xuzhou 221004, China
| | - Yan Du
- Department of Pharmaceutical Analysis, Xuzhou Medical University, Xuzhou 221004, China
| | - Yu-Jie Wang
- Department of Pharmaceutical Analysis, Xuzhou Medical University, Xuzhou 221004, China
| | - Shi-Kai Gao
- Department of Pharmaceutical Analysis, Xuzhou Medical University, Xuzhou 221004, China
| | - Meng-Zhe Guo
- Department of Pharmaceutical Analysis, Xuzhou Medical University, Xuzhou 221004, China; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, China
| | - Dao-Quan Tang
- Department of Pharmaceutical Analysis, Xuzhou Medical University, Xuzhou 221004, China; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, China.
| |
Collapse
|
5
|
Tang D, Chen K, Huang L, Li J. Pharmacokinetic properties and drug interactions of apigenin, a natural flavone. Expert Opin Drug Metab Toxicol 2016; 13:323-330. [DOI: 10.1080/17425255.2017.1251903] [Citation(s) in RCA: 78] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Ding Tang
- Key Laboratory of Education Ministry on Traditional Chinese Medicine Resource and Compound Prescription, Hubei University of Chinese Medicine, Hubei, China
| | - Keli Chen
- Key Laboratory of Education Ministry on Traditional Chinese Medicine Resource and Compound Prescription, Hubei University of Chinese Medicine, Hubei, China
| | - Luqi Huang
- Key Laboratory of Education Ministry on Traditional Chinese Medicine Resource and Compound Prescription, Hubei University of Chinese Medicine, Hubei, China
- State Key Laboratory of Dao-Di Herbs, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China
| | - Juan Li
- Key Laboratory of Education Ministry on Traditional Chinese Medicine Resource and Compound Prescription, Hubei University of Chinese Medicine, Hubei, China
- State Key Laboratory of Dao-Di Herbs, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China
| |
Collapse
|